Connective tissue markers of rheumatoid arthritis

REFERENCES

• Firestein GS. Etiology and pathogenesis of rheu-matoid arthritis. In: Kelley WN, Ruddy S, Harris Jr. ED, Sledge CB, editors. Textbook of rheumatol-ogy. Philadelphia: WB Saunders: 1997: 851–97.
   Google Scholar
• Gardner DL. Problems and paradigms in joint pathology. J Anat 1994; 184: 465–76.
   PubMed Web of Science ®Google Scholar
• Symmons DPM. What is rheumatoid arthritis? Br Med Bull 1995; 51: 243–8.
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
   PubMed Web of Science ®Google Scholar
• Pincus T. Rheumatoid arthritis: a medical emer-gency? Scand J Rheumatol 1994: 21–30.
   Google Scholar
• Symmons DPM, Hassell AB, Gunatillaka KAN, Jones PJ, Schollum J, Dawes PT. Development and preliminary assessment of a simple measure of overall status in rheumatoid arthritis (OSRA) for routine clinical use. Q Mon J Assoc Phys 1995; 88: 429–37.
   PubMedGoogle Scholar
• Visser H, Gelinck LBS, Kamfraath AH, Breedveld FC, Hazes JMW. Diagnostic and prognostic char-acteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 1996; 55: 157–61.
   Google Scholar
• Tighe H, Carson DA. Rheumatoid factors. In: Kelley WN, Ruddy S, Harris Jr. ED, Sledge CB, editors. Textbook of rheumatology. Philadelphia: WB Saunders, 1997: 241–9.
   Google Scholar
• Eberhardt KB, Fex E. Functional impairment and disability in early rheumatoid arthritis—develop-ment over 5 years. J Rheumatol 1995; 22: 1037–42.
   PubMed Web of Science ®Google Scholar
• Pincus T. The case for early intervention in rheuma-toid arthritis. J Autoimmun 1992; 5 Suppl A: 209–26.
   Google Scholar
• Weinblatt ME. Rheumatoid arthritis: treat now, not later Ann Intern Med 1996; 124: 773–4.
   Google Scholar
• Elliott MJ, Feldmann M, Maini RN. TNF alpha blockade in rheumatoid arthritis: Rationale, clini-cal outcomes and mechanisms of action. Int J Immunopharmacol 1995; 17: 141–5.
   Google Scholar
• Strand V, Keystone EC. Biological agents in the treatment of rheumatoid arthritis. In: Kelley WN, Ruddy S, Harris Jr. ED, Sledge CB, editors. Text-book of rheumatology. Philadelphia: WB Saunders, 1997: 839–50.
   Google Scholar
• Emery P, Salmon M, Bradley H, etal. Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. BMJ 1992; 305: 1387–9.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. HLA-DRB1 alleles as severity markers in RA. Bull Rheum Dis 1994; 43: 5–8.
   PubMedGoogle Scholar
• Nepom GT, Gersuk V, Nepom BS. Prognostic implications of HLA genotyping in the early assess-ment of patients with rheumatoid arthritis. J Rheu-matol 1996; 23: 5–9.
   Google Scholar
• Vanzeben D, Breedveld FC. Prognostic factors in rheumatoid arthritis. J Rheumatol 1996; 23: 31–3.
   Google Scholar
• Barland P, Lipstein E. Selection and use of labora-tory tests in the rheumatic diseases. Am J Med 1996; 100: S16–23.
   PubMed Web of Science ®Google Scholar
• Baum J, Ziff M. Laboratory findings in rheumatoid arthritis. In: McCarty DJ, editor. Arthritis and allied conditions. Philadelphia: Lea and Febiger, 1989: 744–61.
   Google Scholar
• Lydyard PM, Edwards JCW. The pathophysiology of rheumatoid arthritis. Clin Exp Rheumatol 1994; 12: S55–8.
   PubMedGoogle Scholar
• Vandeputte LBA, Vanriel PLCM. Rheumatoid arthritis—changing theories and treatment modal-ities. Acta Orthop Scand 1995; 66: 10–3.
   Google Scholar
• Thonar EJ, Shinmei M, Lohmander LS. Body fluid markers of cartilage changes in osteoarthritis. Rheum Dis Clin North Am 1993; 19: 635–57.
   PubMed Web of Science ®Google Scholar
• Myers SL, Brandt KD, Eilam 0. Even low-grade synovitis significantly accelerates the clearance of protein from the canine knee: Implications for mea-surement of synovial fluid 'markers' of osteoarthri-tis. Arthritis Rheum 1995; 38: 1085–91.
   Google Scholar
• Richardson C, Emery P. Laboratory markers of disease activity. J Rheumatol 1996; 23: 23–30.
   Web of Science ®Google Scholar
• Vertel BM. The ins and outs of aggrecan. Tr Cell Biol 1995; 5: 458–64.
   PubMed Web of Science ®Google Scholar
• Valhmu WB, Palmer GD, Rivers PA, et al. Struc-ture of the human aggrecan gene: Exon—intron organization and association with the protein domains. Biochem J 1995; 309: 535–42.
   PubMedGoogle Scholar
• Sandy JD, Plaas AHK, Koob TJ. Pathways of aggrecan processing in joint tissues—implications for disease mechanism and monitoring. Acta Orthop Scand 1995; 66: 26–32.
   Google Scholar
• Saxne T, Heinegard D, Wollheim FA, Pettersson H. Difference in cartilage proteoglycan level in syno-vial fluid in early rheumatoid arthritis and reactive arthritis. Lancet 1985; 2: 127–8.
   PubMed Web of Science ®Google Scholar
• Lindqvist E, Saxne T. Cartilage macromolecules in knee joint synovial fluid. Markers of the disease course in patients with acute oligoarthritis. Ann Rheum Dis 1997; 56: 751–3.
   PubMedGoogle Scholar
• Saxne T, Glennas A, Kvien TK, Melby K, Heinegard D. Release of cartilage macromolecules into the synovial fluid in patients with acute and prolonged phases of reactive arthritis. Arthritis Rheum 1993; 36: 20–5.
   Google Scholar
• Saxne T, Heinegard D. Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions. Arthritis Rheum 1992; 35: 385–90.
   PubMed Web of Science ®Google Scholar
• Saxne T, Heinegard D, Wollheim FA. Cartilage proteoglycans in synovial fluid and serum in patients with inflammatory joint disease. Relation to systemic treatment. Arthritis Rheum 1987; 30: 972–9.
   Google Scholar
• Forslind K, Eberhardt K, Jonsson A, Saxne T. Increased serum concentrations of cartilage oligo-meric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol 1992; 31: 593–8.
   Google Scholar
• Pavelka K, Seibel MJ. Quantitative detection of keratan sulfate specific epitopes in synovial fluid in inflammatory and degenerative joint diseases. Z Rheumatol 1989; 48: 294–300.
   PubMedGoogle Scholar
• Ratcliffe A, Doherty M, Maini RN, Hardingham TE. Increased concentrations of proteoglycan com-ponents in the synovial fluids of patients with acute but not chronic joint disease. Ann Rheum Dis 1988; 47: 826–32.
   PubMed Web of Science ®Google Scholar
• Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J Clin Invest 1994; 94: 25–33.
   PubMed Web of Science ®Google Scholar
• Poole AR, Witter J, Roberts N, et al. Inflammation and cartilage metabolism in rheumatoid arthritis. Studies of the blood markers hyaluronic acid, oro-somucoid, and keratan sulfate. Arthritis Rheum 1990; 33: 790–9.
   PubMedGoogle Scholar
• Seibel MJ, Towbin H, Braun DG, Kiefer B, MUller W, Paulsson M. Serum keratan sulphate in reuma-toid arthritis and different clinical subsets of osteoarthritis. In: Greiling H, Scott JE, editors. Keratan sulphate. Chemistry, biology, chemical pathology. London: The Biochemical Society, 1989: 191–8.
   Google Scholar
• Spector TD, Woodward L, Hall GM, etal. Keratan sulphate in rheumatoid arthritis, osteoarthritis, and inflammatory diseases. Ann Rheum Dis 1992; 51: 1134–7.
   PubMedGoogle Scholar
• Haraoui B, Thonar EJ, Martel Pelletier J, et al. Serum keratan sulfate levels in rheumatoid arthri-tis: inverse correlation with radiographic staging. J Rheumatol 1994; 21: 813–7.
   PubMedGoogle Scholar
• Mehraban F, Finegan CK, Moskowitz RW. Serum keratan sulfate. Quantitative and qualitative com-parisons in inflammatory versus noninflammatory arthritides. Arthritis Rheum 1991; 34: 383–92.
   Google Scholar
• Manicourt DH, Triki R, Fukuda K, Devogelaer JP, Nagant de Deuxchaisnes C, Thonar EJ. Levels of circulating tumor necrosis factor alpha and inter-leukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 1993; 36: 490–9.
   Google Scholar
• Saxne T, Di Giovine FS, Heinegard D, Duff GW, Wollheim FA. Synovial fluid cocentrations of inter-leukin-lâ and proteoglycans are inversely related. J Autoimmun 1988; 1: 373–80.
   PubMedGoogle Scholar
• Moller HJ, Damsgárd TE, Petersen TM, and Poulsen JH. Demonstration of immunogenic kera-tan sulphate in commercial chondroitin 6-sulphate from shark cartilage. Implications for ELISA assays. Clin Chim Acta 1995; 236: 195–204.
   PubMed Web of Science ®Google Scholar
• Moller HJ, Larsen F, Ingemann-Hansen T, and Poulsen JH. ELISA for the core protein of the car-tilage large aggregating proteoglycan, aggrecan: comparison with the concentrations of immuno-genic keratan sulphate in synovial fluid, serum and urine. Clin Chem Acta 1994; 225: 43–55.
   Google Scholar
• Fischer DC, Kolbe Busch S, Stocker G, Hoffmann A, Haubeck HD. Development of enzyme immu-noassays specific for keratan sulphate- and core-protein epitopes of the large aggregating proteogly-can from human articular cartilage. Eur J Clin Chem Clin Biochem 1994; 32: 285–91.
   PubMedGoogle Scholar
• Caterson B, Mahmoodian F, Sorrell JM, et al. Modulation of native chondroitin sulphate struc-ture in tissue development and in disease. J Cell Sci 1990; 97: 411–7.
   PubMed Web of Science ®Google Scholar
• Rizkalla G, Reiner A, Bogoch E, Poole AR. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 1992; 90: 2268–77.
   Google Scholar
• Mansson B, Carey D, Alini M, etal. Cartilage and bone metabolism in rheumatoid arthritis—differ-ences between rapid and slow progression of dis-ease identified by serum markers of cartilage metabolism. J Clin Invest 1995; 95: 1071–7.
   PubMed Web of Science ®Google Scholar
• Fosang AJ, Last K, Gardiner P, Jackson DC, Brown L. Development of a cleavage site-specific monoclonal antibody for detecting metalloprotei-nase-derived aggrecan fragments: Detection of fragments in human synovial fluids. Biochem J 1995; 310: 337–43.
   Google Scholar
• Hughes CE, Caterson B, Fosang AJ, Roughley PJ, Mort JS. Monoclonal antibodies that specifically recognize neoepitope sequences generated by `aggrecanase' and matrix metalloproteinase clea-vage of aggrecan: application to catabolism in situ and in vitro. Biochem J 1995; 305: 799–804.
   Google Scholar
• Lark MW, Williams H, Hoernner LA, etal. Quan-tification of a matrix metalloproteinase-generated aggrecan G1 fragment using monospecific anti-peptide serum. Biochem J 1995; 307: 245–52.
   PubMed Web of Science ®Google Scholar
• Heinegard D, Oldberg A. Structure and biology of cartilage and bone matrix noncollagenous macro-molecules. FASEB J 1989; 3: 2042–51.
   PubMed Web of Science ®Google Scholar
• Oldberg A, Antonsson P, Lindblom K, Heinegard D. COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. J Biol Chem 1992; 267: 22346–50.
   PubMed Web of Science ®Google Scholar
• Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheu-matol 1992; 31: 583–91.
   PubMedGoogle Scholar
• Fex E, Eberhardt K, Saxne T. Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet. Br J Rheumatol 1997; 36: 1161–5.
   Google Scholar
• Neidhart M, Hauser N, Paulsson M, et al. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 1997; 36: 1151–60.
   PubMedGoogle Scholar
• Saxne T, Heinegard D. Involvement of non-articu-lar cartilage, as demonstrated by release of a carti-lage-specific protein, in rheumatoid arthritis. Arthritis Rheum 1989; 32: 1080–6.
   PubMed Web of Science ®Google Scholar
• Engstrom-Laurent A, Hallgren R. Circulating hya-luronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticoster-oid therapy. Ann Rheum Dis 1985; 44: 83–8.
   Google Scholar
• Goldberg RL, Huff JP, Lenz ME, Glickman P, Katz R, Thonar EJ-MA. Elevated plasma levels of hya-luronate in patients with osteoarthritis and rheuma-toid arthritis. Arthritis Rheum 1991; 34: 799–807.
   PubMed Web of Science ®Google Scholar
• Horsley-Petersen K, Bentsen KD, Engstrom Laurent A, Junker P, Halberg P, Lorenzen I. Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflamma-tion during 8 and 24 months' treatment with leva-misole, penicillamine, or azathioprine. Ann Rheum Dis 1988; 47: 116–26.
   Google Scholar
• Paimela L, Heiskanen A, Kurki P, Helve T, Leirisalo Repo M. Serum hyaluronate level as a predictor of radiologic progression in early rheu-matoid arthritis. Arthritis Rheum 1991; 34: 815–21.
   PubMed Web of Science ®Google Scholar
• Sharif M, George E, Dieppe PA. Synovial fluid and serum concentrations of aminoterminal propeptide of type III procollagen in healthy volunteers and patients with joint disease. Ann Rheum Dis 1996; 55: 47–51.
   Google Scholar
• Emlen W, Niebur J, Flanders G, Rutledge J. Mea-surement of serum hyaluronic acid in patients with rheumatoid arthritis: Correlation with disease activity. J Rheumatol 1996; 23: 974–8.
   PubMedGoogle Scholar
• Johansen JS, Jensen HS, Price PA. A new biochem-ical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993; 32: 949–55.
   Google Scholar
• Johansen JS, Hvolris J, Hansen M, et al. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996; 35: 553–9.
   Google Scholar
• Johansen JS, Cintin C, Jorgensen M, Kamby C, Price PA. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. EurJ Cancer 1995; 31: 1437–42.
   Google Scholar
• Johansen JS, Moller S, Price PA, et al. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastro-enterol 1997; 32: 582–90.
   PubMed Web of Science ®Google Scholar
• Gough AK, Peel NF, Eastell R, Holder RL, Lilley J, Emery P. Excretion of pyridinium crosslinks cor-relates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994; 53: 14–7.
   PubMed Web of Science ®Google Scholar
• Hakala M, Risteli L, Manelius J, Nieminen P, Risteli J. Increased type I collagen degradation cor-relates with disease severity in rheumatoid arthritis. Ann Rheum Dis 1993; 52: 866–9.
   Google Scholar
• Saxne T, Zunino L, Heinegard D. Increased release of bone sialoprotein into synovial fluid reflects tis-sue destruction in rheumatoid arthritis. Arthritis Rheum 1995; 38: 82–90.
   Google Scholar
• Beyeler C, Banks RE, Thompson D, Forbes MA, Cooper EH, Bird H. Bone alkaline phosphatase in rheumatic diseases. Ann Clin Biochem 1996; 32: 379–84.
   Google Scholar
• Debri E, Reinholt FP, Heinegard D, Mengarelliwidholm S, Norgard M, Svensson 0. Bone sialoprotein and osteopontin distribution at the osteocartilagineous interface. Clin Orthop 1996; 330: 251–60.
   Google Scholar
• Seibel MJ, Woitge HW, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, Armbruster FP, Ziegler R. Serum immunoreactive bone sialo-protein as a new marker of bone turnover in meta-bolic and malignant bone disease. J Clin Endocrinol Metabol 1996; 81: 3289–94.
   PubMed Web of Science ®Google Scholar